Latest News

Patients with Atopic Dermatitis Are More Susceptible to Developing Inflammatory Bowel Disease
Patients with Atopic Dermatitis Are More Susceptible to Developing Inflammatory Bowel Disease

December 18th 2024

In a meta-analysis of over 61 million participants, it was found that AD patients have a 37% risk of developing IBD and similar conditions.

ICYMI: FDA Approves Galderma's Nemolizumab for Moderate to Severe Atopic Dermatitis in Patients 12 and Older
ICYMI: FDA Approves Galderma's Nemolizumab for Moderate to Severe Atopic Dermatitis in Patients 12 and Older

December 16th 2024

FDA Approves Tapinarof Cream, 1% for Atopic Dermatitis in Patients 2 Years and Older
FDA Approves Tapinarof Cream, 1% for Atopic Dermatitis in Patients 2 Years and Older

December 16th 2024

Arcutis Submits sNDA for Roflumilast Cream 0.05% to FDA for Patients Ages 2 to 5 with Atopic Dermatitis
Arcutis Submits sNDA for Roflumilast Cream 0.05% to FDA for Patients Ages 2 to 5 with Atopic Dermatitis

December 16th 2024

2024 Key Insights: Atopic Dermatitis
2024 Key Insights: Atopic Dermatitis

December 13th 2024

© 2024 MJH Life Sciences

All rights reserved.